CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
Marco BoeriAnna G PurdumJessie SutphinA Brett HauberJames A KayePublished in: Future oncology (London, England) (2021)
Aims: We evaluated physicians' willingness to trade-off benefits, risks and time to infusion for CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Materials & methods: In a discrete-choice experiment survey, 150 US oncologists/hematologists chose between two hypothetical CAR T-cell treatments defined by six attributes. Results: Decreasing time to infusion from 113 to 16 days yielded the greatest change in preference weight (1.91). Physicians were willing to accept a >20% increase in risk of severe cytokine release syndrome and 15% increase in risk of severe neurological events in exchange for an increase in the probability of overall survival at 24 months from 40 to 55%. Conclusion: Physicians value reducing time to infusion and will accept incremental increases in serious adverse event risks to gain survival improvements.
Keyphrases
- diffuse large b cell lymphoma
- primary care
- cell therapy
- epstein barr virus
- low dose
- human health
- early onset
- emergency department
- stem cells
- body mass index
- risk assessment
- mesenchymal stem cells
- weight loss
- physical activity
- acute lymphoblastic leukemia
- case report
- cross sectional
- climate change
- brain injury
- subarachnoid hemorrhage
- decision making
- body weight
- electronic health record